This Obesity Drug Stock Surges 60% on Phase 3 News
A notable fund sold millions of dollars’ worth of shares as this obesity drug stock jumped on Phase 3 momentum. Here’...
Both funds offer diversification; index funds are passive and typically cheaper. This comparison highlights key differences to inform your choice.
24,304 articlesA notable fund sold millions of dollars’ worth of shares as this obesity drug stock jumped on Phase 3 momentum. Here’...
Redwire stock jumped on intraday momentum before giving back gains. This article unpacks the forces behind the pop-a...
Dianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
Major cookware brands file a high-stakes lawsuit against a startup over claims that nonstick pans are toxic, signalin...
DEI labels face political heat, but industry leaders argue the underlying work remains essential for growth and talen...
XRP failed to sustain a move above $1.40 this week, opening the door to downside risk. Here are the latest ripple (xr...
Mizuho ups UnitedHealth's price target to $440, citing easing medical loss ratio pressures and a turning Medicare Adv...
Chase Stokes has sold his South Carolina home for $3 million after completing the final season of Outer Banks, signal...
As investors parse Nano-X Imaging's Q4 2025 results, this guide breaks down the numbers, the business model, and what...
A coalition of 37 European banks plans a euro-denominated stablecoin to challenge dollar rails, targeting wholesale c...
QUBT surged alongside quantum peers on policy chatter, but the rally raises questions about fundamentals and governme...
NVIDIA just crushed earnings on the headline numbers, yet the stock reacted oddly, slipping the next day. This guide ...